{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:17:48Z","timestamp":1788589068167,"version":"build-2803163510"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>While the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and long-term cardiovascular risks has been studied, the impact of MASLD on cardiovascular events during delivery hospitalizations remains relatively unexplored. This study aims to examine the prevalence of cardiovascular diseases (CVDs) and cardiac arrhythmias in pregnant patients with MASLD and identify potential risk factors.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective analysis of hospital discharge records from the National Inpatient Sample database between 2009 and 2019 was conducted to assess maternal cardiovascular outcomes. Multivariable logistic regression models were employed, and adjusted odds ratios (AOR) were calculated to evaluate the association between MASLD and cardiovascular outcomes during pregnancy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The study sample included 17\u2005593 pregnancies with MASLD and 41\u2005171\u2005211 pregnancies without this condition. Women with MASLD exhibited an increased risk of congestive heart failure [AOR 3.45, 95% confidence interval (CI) 1.04\u201311.43], cardiac arrhythmia (AOR 2.60, 95% CI 1.94\u20133.49), and gestational hypertensive complications (AOR 3.30, 95% CI 2.93\u20133.72). Pregnancies with MASLD were also associated with a higher rate of pulmonary edema (AOR 3.30, 95% CI 1.60\u20136.81).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>MASLD is an independent risk factor for cardiovascular complications during delivery hospitalizations, emphasizing the necessity for prepregnancy screening and targeted prevention strategies to manage CVD risks in expectant patients with MASLD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002802","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:03:37Z","timestamp":1718366617000},"page":"1141-1148","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Cardiovascular complications during delivery hospitalizations in patients with nonalcoholic fatty liver disease in pregnancy"],"prefix":"10.1097","volume":"36","author":[{"given":"Chengu","family":"Niu","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Internal Medicine Residency Program, Rochester General Hospital, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Psychiatry Department, Rainier Springs Behavioral Health Hospital, Vancouver, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Khalid","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Zhu","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Internal Medicine Residency Program, Rochester General Hospital, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tausif","family":"Syed","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongli","family":"Liu","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Internal Medicine Residency Program, Rochester General Hospital, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick I.","family":"Okolo","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Rochester General Hospital, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,6]]},"reference":[{"key":"R1-20250801","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R2-20250801","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis.","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"R3-20250801","first-page":"668","article-title":"S2k guideline non-alcoholic fatty liver disease.","volume":"53","author":"Roeb","year":"2015","journal-title":"Z Gastroenterol"},{"key":"R4-20250801","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature.","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"R5-20250801","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD.","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"key":"R6-20250801","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis.","volume":"65","author":"Targher","year":"2016","journal-title":"J Hepatol"},{"key":"R7-20250801","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2337\/dc17-1590","article-title":"Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission.","volume":"41","author":"Wild","year":"2018","journal-title":"Diabetes Care"},{"key":"R8-20250801","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: an analysis of the Framingham heart study.","volume":"63","author":"Mellinger","year":"2015","journal-title":"J Hepatol"},{"key":"R9-20250801","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/HJH.0b013e32833a7de6","article-title":"Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study.","volume":"28","author":"Salvi","year":"2010","journal-title":"J Hypertens"},{"key":"R10-20250801","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/oby.21879","article-title":"Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction.","volume":"25","author":"Simon","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"R11-20250801","doi-asserted-by":"crossref","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment.","volume":"47","author":"Targher","year":"2021","journal-title":"Diabetes Metab"},{"key":"R12-20250801","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1177\/2047487319891783","article-title":"Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease.","volume":"27","author":"Janssen","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R13-20250801","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"key":"R14-20250801","doi-asserted-by":"crossref","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis.","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"key":"R15-20250801","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/gutjnl-2022-328105","article-title":"Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease.","volume":"72","author":"Simon","year":"2023","journal-title":"Gut"},{"key":"R16-20250801","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-20250801","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2036.2011.04579.x","article-title":"Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.","volume":"33","author":"Baranova","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-20250801","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2020.03.049","article-title":"Non-alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes.","volume":"73","author":"Sarkar","year":"2020","journal-title":"J Hepatol"},{"key":"R19-20250801","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cgh.2023.03.031","article-title":"Fatty Liver In Pregnancy (FLIP) Study Group. Prevalence, risk profiles, and national implications of nonalcoholic fatty liver disease in pregnant individuals.","volume":"22","author":"Kushner","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20250801","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"R21-20250801","doi-asserted-by":"crossref","first-page":"bcr2016216802","DOI":"10.1136\/bcr-2016-216802","article-title":"HELLP syndrome: a diagnostic conundrum with severe complications.","volume":"2016","author":"Rao","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R23-20250801","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.115.020491","article-title":"Peripartum cardiomyopathy.","volume":"133","author":"Arany","year":"2016","journal-title":"Circulation"},{"key":"R24-20250801","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","article-title":"NAFLD and cardiovascular diseases: a clinical review.","volume":"110","author":"Kasper","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"R25-20250801","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease.","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"R26-20250801","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation.","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"key":"R27-20250801","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cmet.2019.11.018","article-title":"Hepatic lipoprotein export and remission of human type 2 diabetes after weight loss.","volume":"31","author":"Al-Mrabeh","year":"2020","journal-title":"Cell Metab"},{"key":"R28-20250801","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jgh.12271","article-title":"Characteristics and diagnosis of NAFLD\/NASH.","volume":"28","author":"Hashimoto","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R29-20250801","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjcard.2014.09.044","article-title":"Relation of physical activity to `prevalence of nonalcoholic fatty liver disease independent of cardiometabolic risk.","volume":"115","author":"Oni","year":"2015","journal-title":"Am J Cardiol"},{"key":"R31-20250801","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/CIRCULATIONAHA.121.053963","article-title":"Pravastatin versus placebo in pregnancies at high risk of term preeclampsia.","volume":"144","author":"D\u00f6bert","year":"2021","journal-title":"Circulation"},{"key":"R32-20250801","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/AOG.0b013e3181e9322a","article-title":"Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis.","volume":"116","author":"Bujold","year":"2010","journal-title":"Obstet Gynecol"},{"key":"R33-20250801","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/diseases6040086","article-title":"The role of vitamin E in the treatment of NAFLD.","volume":"6","author":"Perumpail","year":"2018","journal-title":"Diseases"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T17:02:05Z","timestamp":1754067725000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,6]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002802","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,6]]}}}